6533b851fe1ef96bd12a95dc
RESEARCH PRODUCT
Outcomes in Patients Receiving Nintedanib or Pirfenidone for Idiopathic Pulmonary Fibrosis
Manon BelhassenMaeva NolinPhilippe BonniaudKlaus-uwe KirchgässlerTripthi KamathPaolo SpagnoloF. DalonE. Van GanseJenny ChiaVincent Cottinsubject
medicine.medical_specialtybusiness.industryPirfenidonemedicine.diseaseGastroenterologyIdiopathic pulmonary fibrosischemistry.chemical_compoundchemistryInternal medicinemedicineNintedanibIn patientbusinessmedicine.drugyear | journal | country | edition | language |
---|---|---|---|---|
2020-05-01 | A23. ILD PROGNOSIS AND BIOMARKERS I |